Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
3.600
-0.220 (-5.76%)
Mar 28, 2024, 12:32 PM EDT - Market open
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.
In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Inventiva S.A.
Country | France |
Founded | 2011 |
IPO Date | Jul 10, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 117 |
CEO | Frederic Cren |
Contact Details
Address: 50 Rue De Dijon Daix, I0 21121 France | |
Phone | 33380447500 |
Website | inventivapharma.com |
Stock Details
Ticker Symbol | IVA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $14.40 |
CIK Code | 0001756594 |
CUSIP Number | 46124U107 |
ISIN Number | US46124U1079 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Frederic Cren | Co-Founder, Chief Executive Officer and Chairman |
Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer and Director |
Jean Volatier | Chief Financial Officer |
Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
Eric Duranson L.L.M. | General Counsel |
Nathalie Harroy | Head of Human Resources |
Dr. Michael Cooreman | Chief Medical Officer |
Pascaline Clerc Ph.D. | Executive Vice President of Strategy and Corporate Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 6-K | Report of foreign issuer |
Mar 18, 2024 | 6-K | Report of foreign issuer |
Mar 7, 2024 | 6-K | Report of foreign issuer |
Feb 15, 2024 | 6-K | Report of foreign issuer |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 10, 2024 | 6-K | Report of foreign issuer |
Dec 20, 2023 | 6-K | Report of foreign issuer |
Nov 21, 2023 | 6-K | Report of foreign issuer |
Oct 3, 2023 | 6-K/A | Filing |